Brandon Weiss
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Brandon Weiss has a total of 124 co-authors. Here are the top co-authors by number of shared publications:
- Donald R. Lynam
Department of Psychological Sciences Purdue University West Lafayette Indiana USA
9 shared publications - David Erritzoe
Imperial College London
8 shared publications Josh Miller
7 shared publications- Michael L. Crowe
National Center for PTSD, VA Boston Healthcare System
6 shared publications David Erritzoe
Centre for Psychedelic Research, Department of Brain Sciences, Faculty of Medicine, Imperial College London, London, UK
5 shared publications- Robin Lester Carhart-Harris
Department of Neurology, University of California San Francisco, San Francisco, USA
5 shared publications
Latest Publications
- 18 September 2026
- Published by SAGE Publications in Journal of Psychopharmacology
- Vol. 40 (11) , 1862-1876
Validating and creating a short-form of the persisting effects questionnaire: A measure of positive and negative outcomes from psychedelic experiences
Background: The persisting effects questionnaire (PEQ) is a measure of self-reported positive and negative effects from psychedelic and other experiences. While this measure has been used in many studies on psychedelic substances, the scale has not been formally validated. The PEQ consists of over 140 items as well as several separate single items, causing high participant burden. Aims: Conduct statistical and qualitative validation procedures for the PEQ and generate a validated short form version (PEQ-SF). Methods: Validation procedures included (1) conducting exploratory factor analysis for dimensionality reduction, (2) correlations to establish convergent and divergent validity, (3) confirmatory factor analysis in a separate sample, (4) qualitative response process evaluation to ensure items are comprehensible, and (5) comparisons between the original PEQ and the short form in two psychedelic administration studies, one clinical, and one in healthy normals. Results: We found that the factor structure of the original PEQ was not quantitatively supported; factor analysis revealed a two-factor structure consisting of an overall positive and an overall negative factor. This two-factor structure was maintained in a short form version of the scale, consisting of 14 items with one positive valence and one negative valence factor and three single items from the original PEQ related to well-being and meaning. Conclusions: We found that the original PEQ did not have adequate validity and created a short form with strong psychometric properties that behaves similarly in drug administration studies.
- 18 September 2026
- Published by SAGE Publications in Journal of Psychopharmacology
- Vol. 40 (11) , 1862-1876
Validating and creating a short-form of the persisting effects questionnaire: A measure of positive and negative outcomes from psychedelic experiences
Background: The persisting effects questionnaire (PEQ) is a measure of self-reported positive and negative effects from psychedelic and other experiences. While this measure has been used in many studies on psychedelic substances, the scale has not been formally validated. The PEQ consists of over 140 items as well as several separate single items, causing high participant burden. Aims: Conduct statistical and qualitative validation procedures for the PEQ and generate a validated short form version (PEQ-SF). Methods: Validation procedures included (1) conducting exploratory factor analysis for dimensionality reduction, (2) correlations to establish convergent and divergent validity, (3) confirmatory factor analysis in a separate sample, (4) qualitative response process evaluation to ensure items are comprehensible, and (5) comparisons between the original PEQ and the short form in two psychedelic administration studies, one clinical, and one in healthy normals. Results: We found that the factor structure of the original PEQ was not quantitatively supported; factor analysis revealed a two-factor structure consisting of an overall positive and an overall negative factor. This two-factor structure was maintained in a short form version of the scale, consisting of 14 items with one positive valence and one negative valence factor and three single items from the original PEQ related to well-being and meaning. Conclusions: We found that the original PEQ did not have adequate validity and created a short form with strong psychometric properties that behaves similarly in drug administration studies.
- Open Access
- 21 March 2026
- Published by SAGE Publications in Journal of Cerebral Blood Flow & Metabolism
- Vol. 46 (8) , 2125-2137
Detecting neuroplastic effects induced by ketamine in healthy human subjects: A multimodal approach
We investigated ketamine’s neuroplastic effects in healthy human subjects using integrated Positron Emission Tomography (PET)/Magnetic Resonance Imaging (MRI) measures before and 1–8 days after a single psychedelic dose of ketamine (1 mg/kg, intravenous). Eleven male participants underwent two PET/MRI scans with [ 11 C]-UCBJ (synaptic density/plasticity), 1 H-MRS (glutamate and GABA) and resting-state fMRI (intrinsic brain activity, functional connectivity), before and after ketamine. While group-level analyses showed no significant increases in PET synaptic markers, ketamine administration resulted in significantly elevated glutamate levels within the anterior cingulate cortex (ACC). Functional connectivity analyses revealed reduced coupling between the ACC and the dorsolateral prefrontal cortex (dlPFC) and increased coupling between the ACC and the amygdala in the days following ketamine administration. Our multimodal analysis revealed that participants showing an increase in [ 11 C]-UCBJ volume distribution (VT), a putative index of synaptic plasticity, showed a correlated reduction in intrinsic activity within regions belonging to the default mode network (DMN). By linking molecular, cellular and network-level changes, our results point to the DMN as a central hub where ketamine may reshape brain hierarchies in the long term, providing new directions for understanding its therapeutic mechanisms and developing targeted treatments.
- 21 March 2026
- Published by SAGE Publications in Journal of Cerebral Blood Flow & Metabolism
- Vol. 46 (8) , 2125-2137
Open AccessDetecting neuroplastic effects induced by ketamine in healthy human subjects: A multimodal approach
We investigated ketamine’s neuroplastic effects in healthy human subjects using integrated Positron Emission Tomography (PET)/Magnetic Resonance Imaging (MRI) measures before and 1–8 days after a single psychedelic dose of ketamine (1 mg/kg, intravenous). Eleven male participants underwent two PET/MRI scans with [ 11 C]-UCBJ (synaptic density/plasticity), 1 H-MRS (glutamate and GABA) and resting-state fMRI (intrinsic brain activity, functional connectivity), before and after ketamine. While group-level analyses showed no significant increases in PET synaptic markers, ketamine administration resulted in significantly elevated glutamate levels within the anterior cingulate cortex (ACC). Functional connectivity analyses revealed reduced coupling between the ACC and the dorsolateral prefrontal cortex (dlPFC) and increased coupling between the ACC and the amygdala in the days following ketamine administration. Our multimodal analysis revealed that participants showing an increase in [ 11 C]-UCBJ volume distribution (VT), a putative index of synaptic plasticity, showed a correlated reduction in intrinsic activity within regions belonging to the default mode network (DMN). By linking molecular, cellular and network-level changes, our results point to the DMN as a central hub where ketamine may reshape brain hierarchies in the long term, providing new directions for understanding its therapeutic mechanisms and developing targeted treatments.
- 29 December 2025
- Published by Elsevier in General Hospital Psychiatry
- Vol. 99, 30-40
Psychological support can be distinguished from psychotherapy: Clarifications for future empirical work
- 29 December 2025
- Published by Elsevier in General Hospital Psychiatry
- Vol. 99, 30-40
Psychological support can be distinguished from psychotherapy: Clarifications for future empirical work
- 1 December 2025
- Published by SAGE Publications in Psychedelic Medicine
- Vol. 4 (4) , 251-265
The Effect of Psychedelics on Individuals with a Personality Disorder: Results from Two Prospective Cohort Studies
Background: Personality disorders (PDs) are characterized by impairments in psychological functioning for which pharmacologic treatments have demonstrated limited efficacy. Psychedelics may offer a possible PD treatment, given preliminary evidence for their potential long-term positive effects on psychological functioning. However, little is known about the safety or potential therapeutic effects of psychedelics among individuals with a PD. Therefore, we examined the effects of psychedelic use on mental health among individuals who self-reported a PD diagnosis. Methods: Study 1 included data from three prospective observational studies where 21 individuals who reported a PD diagnosis completed mental health measures (depression symptoms, anxiety, and suicidal ideation [SI]) before, 2 weeks, and 4 weeks after psychedelic use. Study 2 involved a prospective observational study where 55 individuals who reported a PD diagnosis completed mental health measures (depressive symptoms, anxiety, cognitive flexibility, expressive suppression, and cognitive reappraisal) before, 2–4 weeks, and 2–3 months after psychedelic use. Results: In Study 1, all participants with high baseline risk of suicidal behavior (6.67%) became low-risk post-psychedelic use. Post-psychedelic increases in SI were rare (6.67%) with no increases to high risk of suicidal behavior. SI reduced at 4 weeks (Hedges’ g = 0.52). There were several cases of clinically significant worsening of anxiety (Study 1: 0%; Study 2: 7.7 − 8.2%) and depression symptoms (Study 1: 0 − 7.1%; Study 2: 0%). However, across both studies, psychedelic use was associated with reductions in anxiety (Study 1: g = −0.46 to −0.57; Study 2: g = −0.52 to −0.89) and depression (Study 1: g = −0.54 to −0.59; Study 2: r s = 0.52–0.57). In Study 2, there were transient increases in cognitive flexibility at 2–4 weeks ( g = 0.26) and sustained increases in cognitive reappraisal up to 2–3 months ( g = 0.36). Increases in cognitive reappraisal were associated with reductions in anxiety ( r = −0.33) and depression ( r s = −0.37). Conclusion: Psychedelic use was on average associated with improvements in mental health outcomes for individuals who self-reported a PD diagnosis. There were no clinically significant post-psychedelic increases in SI, but there were a few cases of clinically significant increases in anxiety and depression severity. These preliminary findings are limited by the small sample size, self-reported data, and lack of differentiation between PDs. Further research is needed to explore the safety and potential therapeutic effects of psychedelics among individuals with a PD.
- 1 December 2025
- Published by SAGE Publications in Psychedelic Medicine
- Vol. 4 (4) , 251-265
The Effect of Psychedelics on Individuals with a Personality Disorder: Results from Two Prospective Cohort Studies
Background: Personality disorders (PDs) are characterized by impairments in psychological functioning for which pharmacologic treatments have demonstrated limited efficacy. Psychedelics may offer a possible PD treatment, given preliminary evidence for their potential long-term positive effects on psychological functioning. However, little is known about the safety or potential therapeutic effects of psychedelics among individuals with a PD. Therefore, we examined the effects of psychedelic use on mental health among individuals who self-reported a PD diagnosis. Methods: Study 1 included data from three prospective observational studies where 21 individuals who reported a PD diagnosis completed mental health measures (depression symptoms, anxiety, and suicidal ideation [SI]) before, 2 weeks, and 4 weeks after psychedelic use. Study 2 involved a prospective observational study where 55 individuals who reported a PD diagnosis completed mental health measures (depressive symptoms, anxiety, cognitive flexibility, expressive suppression, and cognitive reappraisal) before, 2–4 weeks, and 2–3 months after psychedelic use. Results: In Study 1, all participants with high baseline risk of suicidal behavior (6.67%) became low-risk post-psychedelic use. Post-psychedelic increases in SI were rare (6.67%) with no increases to high risk of suicidal behavior. SI reduced at 4 weeks (Hedges’ g = 0.52). There were several cases of clinically significant worsening of anxiety (Study 1: 0%; Study 2: 7.7 − 8.2%) and depression symptoms (Study 1: 0 − 7.1%; Study 2: 0%). However, across both studies, psychedelic use was associated with reductions in anxiety (Study 1: g = −0.46 to −0.57; Study 2: g = −0.52 to −0.89) and depression (Study 1: g = −0.54 to −0.59; Study 2: r s = 0.52–0.57). In Study 2, there were transient increases in cognitive flexibility at 2–4 weeks ( g = 0.26) and sustained increases in cognitive reappraisal up to 2–3 months ( g = 0.36). Increases in cognitive reappraisal were associated with reductions in anxiety ( r = −0.33) and depression ( r s = −0.37). Conclusion: Psychedelic use was on average associated with improvements in mental health outcomes for individuals who self-reported a PD diagnosis. There were no clinically significant post-psychedelic increases in SI, but there were a few cases of clinically significant increases in anxiety and depression severity. These preliminary findings are limited by the small sample size, self-reported data, and lack of differentiation between PDs. Further research is needed to explore the safety and potential therapeutic effects of psychedelics among individuals with a PD.
- Open Access
- 1 July 2025
- Published by Center for Open Science in PsyArXiv
Ink and Identity: Personality Perceptions Based on Tattoos
People with and without tattoos are often judged differently, but previous research often neglects the type and characteristics of tattoos. We examined these questions in 274 adults (Mage = 24.59, SD = 7.17; 71.2% women; 77.2% White) with 375 tattoos who agreed to have their tattoos photographed for the study and completed a battery of personality measures. Although there was consensus about the personalities of people who had a particular tattoo (i.e., judges agreed in their perceptions of people with tattoos), these judgments were largely inaccurate, with a few exceptions. Specifically, judgments of openness to experience (based solely on tattoos) were modestly accurate and attributable to how “wacky” the tattoo was.
- 1 July 2025
- Published by Center for Open Science in PsyArXiv
Open AccessInk and Identity: Personality Perceptions Based on Tattoos
People with and without tattoos are often judged differently, but previous research often neglects the type and characteristics of tattoos. We examined these questions in 274 adults (Mage = 24.59, SD = 7.17; 71.2% women; 77.2% White) with 375 tattoos who agreed to have their tattoos photographed for the study and completed a battery of personality measures. Although there was consensus about the personalities of people who had a particular tattoo (i.e., judges agreed in their perceptions of people with tattoos), these judgments were largely inaccurate, with a few exceptions. Specifically, judgments of openness to experience (based solely on tattoos) were modestly accurate and attributable to how “wacky” the tattoo was.
- Open Access
- 2 December 2024
- Published by Elsevier in Neuroscience Applied
- Vol. 4, 104092
An investigation of acute physiological and psychological moderators of psychedelic-induced personality change among healthy volunteers
- 2 December 2024
- Published by Elsevier in Neuroscience Applied
- Vol. 4, 104092
Open AccessAn investigation of acute physiological and psychological moderators of psychedelic-induced personality change among healthy volunteers
- Open Access
- 15 October 2024
- Published by Springer Nature in Research Square
The Effect of Psychedelics on Individuals with a Personality Disorder: Results from two Prospective Cohort Studies
Background: Personality disorders (PDs) are characterized by impairments in psychological functioning for which pharmacologic treatments have demonstrated limited efficacy. Psychedelics may offer a possible PD treatment, given preliminary evidence for their potential long-term positive effects on psychological functioning. However, little is known about safety or potential therapeutic effects of psychedelics among individuals with a PD. Therefore, we examined the effects of psychedelic use on mental health among individuals who reported a PD diagnosis. Methods: Study 1 included three prospective observational studies where 21 individuals who reported a PD diagnosis completed mental health measures (depression symptoms, anxiety, and suicidal ideation [SI]) before, 2 weeks, and 4 weeks after psychedelic use. Study 2 was a prospective observational study where 55 individuals who reported a PD diagnosis completed mental health measures (anxiety, depressive symptoms, cognitive flexibility, expressive suppression, and cognitive reappraisal) before, 2-4 weeks, and 2-3 months after psychedelic use. Results: In Study 1, all participants with high baseline risk of suicidal behavior (6.67%) became low-risk post-psychedelic use. Post-psychedelic increases in SI were rare (6.67%) with no increases to high risk of suicidal behavior. SI reduced at 4 weeks (Hedges’ g=0.52). There were few cases of clinically significant worsening anxiety (Study 1:0.0%; Study 2:7.7%-8.2%) and depression symptoms (Study 1:0.0%-7.1%; Study 2:0.0%). However, across both studies, psychedelic use was associated with reductions in anxiety (Study 1:g=-0.46–-0.57; Study 2:g=-0.52–-0.89) and depression (Study 1 g=-0.54–-0.59; Study 2 rs=.52–.57). In Study 2, there were transient increases in cognitive flexibility at 2-4 weeks (g=0.26) and sustained increases in cognitive reappraisal up to 2-3 months (g=0.36). Increases in cognitive reappraisal were associated with reductions in anxiety (r=-.33) and depression (rs=-.37). Conclusion: For individuals who reported a PD diagnosis, psychedelic use was associated with improvements in mental health outcomes. There were no clinically significant post-psychedelic increases in SI but there were a few cases of clinically significant increases in anxiety and depression severity. The studies are limited by a small sample size, self-reported data, and lack of differentiation between PDs. Further research is needed to explore the safety and potential therapeutic effects of psychedelics among individuals with PD.
- 15 October 2024
- Published by Springer Nature in Research Square
Open AccessThe Effect of Psychedelics on Individuals with a Personality Disorder: Results from two Prospective Cohort Studies
Background: Personality disorders (PDs) are characterized by impairments in psychological functioning for which pharmacologic treatments have demonstrated limited efficacy. Psychedelics may offer a possible PD treatment, given preliminary evidence for their potential long-term positive effects on psychological functioning. However, little is known about safety or potential therapeutic effects of psychedelics among individuals with a PD. Therefore, we examined the effects of psychedelic use on mental health among individuals who reported a PD diagnosis. Methods: Study 1 included three prospective observational studies where 21 individuals who reported a PD diagnosis completed mental health measures (depression symptoms, anxiety, and suicidal ideation [SI]) before, 2 weeks, and 4 weeks after psychedelic use. Study 2 was a prospective observational study where 55 individuals who reported a PD diagnosis completed mental health measures (anxiety, depressive symptoms, cognitive flexibility, expressive suppression, and cognitive reappraisal) before, 2-4 weeks, and 2-3 months after psychedelic use. Results: In Study 1, all participants with high baseline risk of suicidal behavior (6.67%) became low-risk post-psychedelic use. Post-psychedelic increases in SI were rare (6.67%) with no increases to high risk of suicidal behavior. SI reduced at 4 weeks (Hedges’ g=0.52). There were few cases of clinically significant worsening anxiety (Study 1:0.0%; Study 2:7.7%-8.2%) and depression symptoms (Study 1:0.0%-7.1%; Study 2:0.0%). However, across both studies, psychedelic use was associated with reductions in anxiety (Study 1:g=-0.46–-0.57; Study 2:g=-0.52–-0.89) and depression (Study 1 g=-0.54–-0.59; Study 2 rs=.52–.57). In Study 2, there were transient increases in cognitive flexibility at 2-4 weeks (g=0.26) and sustained increases in cognitive reappraisal up to 2-3 months (g=0.36). Increases in cognitive reappraisal were associated with reductions in anxiety (r=-.33) and depression (rs=-.37). Conclusion: For individuals who reported a PD diagnosis, psychedelic use was associated with improvements in mental health outcomes. There were no clinically significant post-psychedelic increases in SI but there were a few cases of clinically significant increases in anxiety and depression severity. The studies are limited by a small sample size, self-reported data, and lack of differentiation between PDs. Further research is needed to explore the safety and potential therapeutic effects of psychedelics among individuals with PD.
- Top Cited PapersOpen Access
- 23 September 2024
- Published by Elsevier in eClinicalMedicine
- Vol. 76, 102799
Effect of psilocybin versus escitalopram on depression symptom severity in patients with moderate-to-severe major depressive disorder: observational 6-month follow-up of a phase 2, double-blind, randomised, controlled trial
- 23 September 2024
- Published by Elsevier in eClinicalMedicine
- Vol. 76, 102799
Top Cited PapersOpen AccessEffect of psilocybin versus escitalopram on depression symptom severity in patients with moderate-to-severe major depressive disorder: observational 6-month follow-up of a phase 2, double-blind, randomised, controlled trial
- Open Access
- 7 March 2024
- Published by Springer Nature in International Journal of Mental Health and Addiction
- Vol. 22 (2) , 806-841
Unique Psychological Mechanisms Underlying Psilocybin Therapy Versus Escitalopram Treatment in the Treatment of Major Depressive Disorder
The mechanisms by which Psilocybin Therapy (PT) improves depression remain an important object of study, with scientists actively exploring acute psychological experiences and neurobiological processes as candidates. In a phase 2, double-blind, randomized, active comparator controlled trial involving patients with moderate-to-severe major depressive disorder, we investigated whether acute psychological experiences could meaningfully account for the unique efficacy of PT versus Escitalopram Treatment over a core 6-week trial period. An exploratory-factor-analysis-derived single-factor of depression was used as the outcome. Among a comprehensive set of acute experiences related to psilocybin, so-called “mystical experience” and “ego dissolution” were unique in mediating the effect of treatment condition on depressive response with high specificity. Higher reported levels of mystical experience, emotional breakthrough, and intense responses to music-listening were furthermore associated with greater antidepressant response. These results provide qualified support for the causal mechanistic role of acute psychological experiences in the treatment of depression via PT.
- 7 March 2024
- Published by Springer Nature in International Journal of Mental Health and Addiction
- Vol. 22 (2) , 806-841
Open AccessUnique Psychological Mechanisms Underlying Psilocybin Therapy Versus Escitalopram Treatment in the Treatment of Major Depressive Disorder
The mechanisms by which Psilocybin Therapy (PT) improves depression remain an important object of study, with scientists actively exploring acute psychological experiences and neurobiological processes as candidates. In a phase 2, double-blind, randomized, active comparator controlled trial involving patients with moderate-to-severe major depressive disorder, we investigated whether acute psychological experiences could meaningfully account for the unique efficacy of PT versus Escitalopram Treatment over a core 6-week trial period. An exploratory-factor-analysis-derived single-factor of depression was used as the outcome. Among a comprehensive set of acute experiences related to psilocybin, so-called “mystical experience” and “ego dissolution” were unique in mediating the effect of treatment condition on depressive response with high specificity. Higher reported levels of mystical experience, emotional breakthrough, and intense responses to music-listening were furthermore associated with greater antidepressant response. These results provide qualified support for the causal mechanistic role of acute psychological experiences in the treatment of depression via PT.